Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Interpace Diagnostics Group ( (IDXG) ) has shared an announcement.
Interpace Biosciences reported preliminary, unaudited 2025 revenue from continuing operations of approximately $38–39 million, of which $34–35 million came from thyroid testing, reflecting 21% growth in thyroid testing revenue over 2024 following the discontinuation of its PancraGEN test in May 2025 and a full pivot to its thyroid diagnostics franchise. The company issued initial 2026 revenue guidance of about $40 million, all from thyroid testing, and further simplified its balance sheet by confirming that, after an October 2024 exchange of Series B into Series C preferred shares, all Series C preferred stock has now been converted into roughly 23.3 million common shares, leaving about 27.7 million basic shares outstanding, a debt-free balance sheet, and a fully common equity capital structure; with majority ownership held by private equity investors 1315 Capital and Ampersand, Interpace plans to leverage its improved financial position and profitability to seek an uplisting to the Nasdaq Stock Market in 2026, a move that could broaden its investor base and support additional investment in sales, R&D, and lab automation.
The most recent analyst rating on (IDXG) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Interpace Diagnostics Group stock, see the IDXG Stock Forecast page.
Spark’s Take on IDXG Stock
According to Spark, TipRanks’ AI Analyst, IDXG is a Neutral.
The stock score is primarily driven by strong financial performance and undervaluation, despite technical indicators suggesting overbought conditions. The company’s strategic debt repayment further supports its growth potential, although negative equity remains a concern.
To see Spark’s full report on IDXG stock, click here.
More about Interpace Diagnostics Group
Interpace Biosciences is a molecular diagnostics company focused on enabling personalized medicine, providing clinical services through Interpace Diagnostics that include molecular diagnostic tests, bioinformatics and pathology services to evaluate cancer risk. The company’s commercial portfolio now centers on two thyroid cancer tests—ThyGeNEXT, a next-generation sequencing assay for diagnosing thyroid cancer from nodules, and ThyraMIRv2, a companion microRNA-based test used with ThyGeNEXT for algorithmic classification of thyroid malignancy risk.
Average Trading Volume: 11,366
Technical Sentiment Signal: Hold
Current Market Cap: $5.54M
See more insights into IDXG stock on TipRanks’ Stock Analysis page.